5. Conclusions
DISEASE, PATHOLOGY
In conclusion, based on findings observed in skin biopsies and blood of patients with moderate-to-severe HS, 8 weeks of treatment with the JAK1 inhibitor povorcitinib was associated with the reversal of a previously identified HS transcriptomic signature, as well as dose-dependent changes in a number of circulating proteins that may contribute to disease pathology. In agreement with the mechanism of action of povorcitinib, many observed changes involved pathways modulated by JAK/STAT signaling. Other biomarker changes seemed to reflect the clinical efficacy findings and therefore highlight the potential of JAK1 inhibition to modulate the underlying disease pathology in HS.